July 15, 2025

Figure 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

View Full Paper

Ask AI

Bookmark

Main finding shows distinct plasma concentration profiles for PF-06873600 in patients with breast cancer.
Key evidence indicates median plasma levels measured after single and multiple oral doses on specific days.
Approach involves tracking concentration-time profiles for both immediate and modified release formulations.
Significance lies in optimizing treatment strategies for breast cancer through understanding drug kinetics.

Discussion

No takes yet. Share an insight, caveat, or question.

First-in-human trial demonstrates plasma concentration profiles of PF-06873600 in breast cancer, suggesting insights into therapy effects.

Yap et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

First-in-human trial demonstrates plasma concentration profiles of PF-06873600 in breast cancer, suggesting insights into therapy effects.